News | June 08, 2024
Briefs: Concord Biotech and Shelter Pharma
Shelter Pharma Limited secured an order from Berlin International Medical Co D3Cure 50 ml x 30000 pcs
Shelter Pharma Limited secured an order from Berlin International Medical Co D3Cure 50 ml x 30000 pcs
Oligonucleotides are a unique modality with potential to address hard-to-treat diseases with high unmet need
Canagliflozin and Metformin Hydrochloride Tablets are used to treat type 2 diabetes mellitus
Vonoprozan is a novel potassium-competitive acid blocker used for the treatment of acid related disorders
PICCOLO trial met its primary endpoint of objective response rate (ORR)
Updated analysis from Memorial Sloan Kettering Cancer Center presented at ASCO 2024 has expanded to 42 patients with clinical complete response
Recommendation based on FLAURA2 results which showed Tagrisso plus chemotherapy extended median progression-free survival by nearly 9 months
Merck shared updates on the company’s oncology pipeline and focused R&D approach
Facility in The Woodlands, Texas to produce critical starting material for cell and gene therapy, DNA/RNA-based, and recombinant protein therapeutics in Q1/2025
Partnership to facilitate collaborative research in academia and industry to further progress in life sciences
Subscribe To Our Newsletter & Stay Updated
